BR112015022415A2 - composições de cisplatina lipossômica para terapia contra câncer - Google Patents

composições de cisplatina lipossômica para terapia contra câncer

Info

Publication number
BR112015022415A2
BR112015022415A2 BR112015022415A BR112015022415A BR112015022415A2 BR 112015022415 A2 BR112015022415 A2 BR 112015022415A2 BR 112015022415 A BR112015022415 A BR 112015022415A BR 112015022415 A BR112015022415 A BR 112015022415A BR 112015022415 A2 BR112015022415 A2 BR 112015022415A2
Authority
BR
Brazil
Prior art keywords
cisplatin
cancer therapy
mol
liposomal
liposomal cisplatin
Prior art date
Application number
BR112015022415A
Other languages
English (en)
Inventor
Mcghee William
Original Assignee
Mallinckrodt Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Llc filed Critical Mallinckrodt Llc
Publication of BR112015022415A2 publication Critical patent/BR112015022415A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Abstract

resumo patente de invenção: "composições de cisplatina lipossômica para terapia contra câncer". a presente invenção fornece uma composição para o tratamento de câncer que inclui lipossomas zwitteriônicos que consistem essencialmente em: 50 a 65% em mol de um lipídeo de fosfatidilcolina, 30 a 45% em mol de colesterol e 2 a 8% em mol de um peg-lipídio; e cisplatina. a cisplatina é encapsulada nos lipossomas em uma quantidade de modo que a razão do peso total de lipídio para o peso de cisplatina seja de cerca de 65:1 a cerca de 95:1. os métodos para a preparação de cisplatina lipossômica e o tratamento de câncer são também revelados.
BR112015022415A 2013-03-13 2014-03-13 composições de cisplatina lipossômica para terapia contra câncer BR112015022415A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780272P 2013-03-13 2013-03-13
PCT/US2014/026341 WO2014160337A1 (en) 2013-03-13 2014-03-13 Liposomal cisplatin compositions for cancer therapy

Publications (1)

Publication Number Publication Date
BR112015022415A2 true BR112015022415A2 (pt) 2017-07-18

Family

ID=50439522

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022415A BR112015022415A2 (pt) 2013-03-13 2014-03-13 composições de cisplatina lipossômica para terapia contra câncer

Country Status (8)

Country Link
US (2) US10039716B2 (pt)
EP (1) EP2968142A1 (pt)
JP (1) JP6077710B2 (pt)
CN (1) CN105209017A (pt)
BR (1) BR112015022415A2 (pt)
CA (1) CA2903254C (pt)
MX (1) MX2015012199A (pt)
WO (1) WO2014160337A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5994049B2 (ja) * 2012-10-01 2016-09-21 兵神装備株式会社 吐出システム
EP3265063A4 (en) * 2015-03-03 2018-11-07 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
EP3265059A4 (en) 2015-03-03 2018-08-29 Cureport Inc. Combination liposomal pharmaceutical formulations
US20170049701A1 (en) * 2015-08-05 2017-02-23 Steven M. Kushner Clustoidal multilamellar soy lecithin phospholipid structures for transdermal, transmucosal, or oral delivery, improved intestinal absorption, and improved bioavailability of nutrients
EP3352733A1 (en) * 2015-09-21 2018-08-01 Mallinckrodt LLC Improved stability of liposome formulations and uses thereof
JP6697541B2 (ja) * 2016-01-07 2020-05-20 ウエスタン ユニバーシティ オブ ヘルス サイエンシーズ 膀胱癌処置のための処方物
EP3416623B1 (en) * 2016-02-15 2021-08-11 University of Georgia Research Foundation, Inc. Ipa-3-loaded liposomes and methods of use thereof
MX2018013640A (es) * 2016-05-16 2019-08-01 Infectious Disease Res Inst Liposomas pegiladas y metodos de uso.
WO2018136002A1 (en) * 2017-01-18 2018-07-26 Temasek Life Sciences Laboratory Limited Hyperstabilized liposomes increase targeting of mitotic cells
EP3706801A4 (en) * 2017-11-08 2022-04-06 L.E.A.F Holdings Group LLC PLATINUM COMPLEXES AND THEIR USES
TW202345843A (zh) * 2022-04-06 2023-12-01 財團法人國家衛生研究院 脂質奈米顆粒及脂質體

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843473A (en) * 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
US20020009488A1 (en) * 1995-05-03 2002-01-24 Polymasc Pharmaceuticals Plc Tissue entrapment
ATE252372T1 (de) * 1996-08-23 2003-11-15 Sequus Pharm Inc Liposome enthaltend cisplatin
IL131008A (en) 1997-02-05 2003-06-24 Upjohn Co Lipid complexes and liposomes of highly insoluble platinum complex dicarboxylate
IL150483A0 (en) 2000-01-28 2002-12-01 Alza Corp Liposomes containing an entrapped compound in supersaturated solution
AU2002225878A1 (en) * 2000-11-02 2002-05-15 Smith Kline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
EP1448165B1 (en) * 2001-11-13 2007-09-19 Celator Pharmaceuticals, Inc. Lipid carrier compositions and methods for improved drug retention
EP1674081A1 (de) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
EP1716870A1 (en) * 2005-04-29 2006-11-02 Bracco Imaging S.p.A. MRI contrast agents endowed with concentration independent responsiveness
EP2090305A4 (en) 2006-12-08 2012-12-26 Katayama Chemical Ind Co Ltd LIPOSOME ENCAPSULATING HIGH-CONCENTRATION <O> AMINE </ O> COMPLEX, AND PROCESS FOR PRODUCING THE SAME

Also Published As

Publication number Publication date
CA2903254C (en) 2019-04-09
WO2014160337A1 (en) 2014-10-02
US20180318219A1 (en) 2018-11-08
CN105209017A (zh) 2015-12-30
US10383823B2 (en) 2019-08-20
JP2016513651A (ja) 2016-05-16
CA2903254A1 (en) 2014-10-02
US20140271821A1 (en) 2014-09-18
JP6077710B2 (ja) 2017-02-08
US10039716B2 (en) 2018-08-07
EP2968142A1 (en) 2016-01-20
MX2015012199A (es) 2015-11-30

Similar Documents

Publication Publication Date Title
BR112015022415A2 (pt) composições de cisplatina lipossômica para terapia contra câncer
BR112015022476A2 (pt) composições de oxaliplatina de lipossoma para terapia de câncer
BR112015022819A8 (pt) método para a preparação de um taxano lipossomal, composição compreendendo um lipossoma e taxano lipossomal
CY1123945T1 (el) Στοματικα σκευασματα αμεσης απελευθερωσης για υποκατεστημενες κιναζολινονες
PH12016502132A1 (en) Aryl-or heteroaryl-substituted benzene compounds
BR112014015333A8 (pt) composições lipossomais de clorito ou clorato
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
BR112014010291A2 (pt) composições de lipossoma combinacionais para terapia de câncer
AR091006A1 (es) Formulaciones de testosterona proliposomal
BR112015008487A2 (pt) compostos de benzeno substituído
BR112015008447A2 (pt) métodos para tratar câncer
EA201500535A1 (ru) Применение akkermansia muciniphila для лечения метаболических расстройств, увеличения расхода энергии и насыщения, снижения веса, композиция, фармацевтическая композиция, косметическая композиция и лекарственное средство
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
GEP201706734B (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
BR112015023153A2 (pt) utilização de um composto e composto
BR112013010556A2 (pt) métodos e composições adequadas para a promoção de uma pele saudável
IN2015DN03219A (pt)
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
BR112015001313A2 (pt) composições de vacina
BR112012012862A2 (pt) composição farmacêutica compreendendo oligopeptídeos
BR112013024824A2 (pt) ésteres isopentílicos para uso em composições cosméticas, dermatológicas ou farmacêuticas
BR112012027092A2 (pt) métodos e composiões para reduzir ou impedir a calcificação vascular durante a terapia de diálise peritoneal
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
BR112013026698A2 (pt) formulações do tipo tópica compreendendo depsipeptídeo cíclico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2623 DE 13/04/2021.